Opinion|Videos|February 17, 2025
Advancing to Systemic Treatment in an 8-Year-Old Girl With Atopic Dermatitis
Author(s)Raj Chovatiya, MD, PhD, MSCI
The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy. Treatment goals include reducing inflammation, improving quality of life, and providing age-appropriate, empathetic care while addressing patient and caregiver concerns about efficacy and safety.
Advertisement
Episodes in this series
Video content above is provided by the following:
- Please share your impressions of the case. What aspects of the case are most relevant for treatment consideration?
- What are your treatment goals for this patient?
- Describe your approach to pharmacologic treatment for this patient. Would her history and presentation make her a candidate for systemic therapy?
- How do you approach the conversation with pediatric patients and their caregivers when initiating a systemic, injectable treatment for atopic dermatitis?
- What should this patient expect in terms of efficacy and safety with dupilumab? How soon can she expect initial symptom relief?
- How would you address potential patient/caregiver concerns such as fear of injections or adverse effects and long-term safety with dupilumab?
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
5